Navigation Links
American College of Cardiology/American Heart Association Comment on the FDA Public Health Advisory Regarding a Drug Interaction Between Clopidogrel and Omeprazole
Date:11/17/2009

ORLANDO, Fla., Nov. 17 /PRNewswire-USNewswire/ -- Today the FDA notified healthcare professionals of new safety information concerning a drug interaction between clopidogrel, an anti-clotting medication, and omeprazole, a proton pump inhibitor (PPI) used to reduce stomach acid.

The FDA notes that they have new data showing that when healthy volunteers received clopidogrel with omeprazole, clopidogrel was less effective in its anti-clotting action than when given without omeprazole. The data are not yet peer-reviewed and published; however the FDA recommends that patients who are using clopidogrel should consult with their healthcare provider if they are currently taking or considering taking omeprazole, including Prilosec OTC.

Clopidogrel is often prescribed to people who have chest pain, have had a heart attack or undergone an artery-opening procedure such as angioplasty or stenting. Effective anti-clotting therapy is proven to reduce the risk of another heart event.

Since clopidogrel can cause bleeding in the stomach, medications like omeprazole may be used in combination to reduce stomach acid and prevent stomach bleeding. Omeprazole is available both by prescription and as an over-the-counter preparation (Prilosec OTC) used to treat frequent heartburn.

The FDA public health advisory lists other medications including antacids and medicines that reduce stomach acid (ranitidine, famotidine, nizatidine) that do not interfere with the anti-clotting activity of clopidogrel, but they suggest that cimetidine should not be used.

The FDA's statement is not based on any new published, peer-reviewed clinical trials showing changes in cardiovascular outcomes.

Visit http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm110594.htm for the full FDA announcement.

The American Heart Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) that also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.

SOURCE American Heart Association; American College of Cardiology


'/>"/>
SOURCE American Heart Association; American College of Cardiology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Highlights of NHLBI-supported research presented at American Heart Associations Scientific Sessions
2. Mississippi Baptist Medical Center Receives American College of Cardiology Foundation's NCDR ACTION Registry-GWTGTM Gold Performance Achievement Award
3. The ZigBee Alliance and the American Telemedicine Association to Collaborate on Advancing Use of Telehealth Solutions
4. United American Healthcare Corporation Announces Fiscal 2010 First Quarter Results
5. American Heart Association Late Breaking Clinical Trial Report: In Patients on Statins, Raising Good Cholesterol with Niacin, but not Reducing Bad Cholesterol with Ezetimibe, Decreases Plaque Build-Up
6. American Heart Associations Scientific Sessions Media Alert
7. American Heart Association Late Breaking Clinical Trial Report: Tests Predict Which Patients Are Resistant to Anti-Clotting Therapy During Angioplasty, Stenting
8. LTC Awareness Month Finds Americans Still in Dark about Long-Term Care
9. New Poll Finds 71 Percent of Americans Favor Investing More in Disease Prevention as Central to Health Reform
10. Regence Recognized as an American Heart Association Start! Fit-Friendly Company
11. African-Americans with colorectal cancer have poorer outcomes, lower survival rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... Oct. 4, 2017  According to the Centers for Disease Control and ... October . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the ... certain health insurance regulations. ... time to get a flu shot is by the end of October, ...
(Date:10/2/2017)... ORLANDO, Fla. , Oct. 2, 2017  AllianceRx ... services company formed by Walgreens and pharmacy benefit manager ... of its new brand, which included the unveiling of ... Fla. , as well as at a few ... introduces the new brand to patients, some of whom ...
Breaking Medicine Technology: